Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Vile

Showing results (1-10 of 91) with videos related to

Pageof 10
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 4, 2010
Oncolytic viruses: now interviewing for the all-star gameRichard Vile
Nature Medicine|May 6, 2006
Virus smuggling, tax evasion and tumor assassinationKevin Harrington, Richard Vile
Cancer Gene Therapy|March 24, 2026
The TCR in CAR T cell therapy: use it or lose it?Olivia Liseth, Richard Vile
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 5, 2011
An intravenous stimulus package for oncolytic virotherapyRichard Vile, Alan Melcher
Oncoimmunology|March 14, 2013
Improving the outcome of adoptive cell transfer by targeting tumor escapeKaren M Kaluza, Richard Vile
Cancer Gene Therapy|January 11, 2003
The oncolytic virotherapy treatment platform for cancer: unique biological and biosafety points to considerRichard Vile, Dale Ando, David Kirn
Science (New York, N.Y.)|December 9, 2021
Oncolytic virotherapy as immunotherapyAlan Melcher, Kevin Harrington, Richard Vile
The New England Journal of Medicine|September 9, 2008
Cancer immunotherapyRobin Prestwich, Richard Vile, Alan Melcher
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 2, 2009
Oncolytic viruses: time to compare, contrast, and combine? 5th international meeting on replicating oncolytic virus therapeutics. Banff, Alberta, Canada, 18-22 March 2009Hardev Pandha, Alan Melcher, Kevin Harrington, et al.
Oncotarget|September 12, 2012
The hitchhiker's guide to virotherapyOliver Donnelly, Richard Vile, Hardev Pandha, et al.
Pageof 10

Showing results (1-10 of 91) with videos related to

Sort By:
Pageof 10
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 4, 2010
Oncolytic viruses: now interviewing for the all-star gameRichard Vile
Nature Medicine|May 6, 2006
Virus smuggling, tax evasion and tumor assassinationKevin Harrington, Richard Vile
Cancer Gene Therapy|March 24, 2026
The TCR in CAR T cell therapy: use it or lose it?Olivia Liseth, Richard Vile
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 5, 2011
An intravenous stimulus package for oncolytic virotherapyRichard Vile, Alan Melcher
Oncoimmunology|March 14, 2013
Improving the outcome of adoptive cell transfer by targeting tumor escapeKaren M Kaluza, Richard Vile
Cancer Gene Therapy|January 11, 2003
The oncolytic virotherapy treatment platform for cancer: unique biological and biosafety points to considerRichard Vile, Dale Ando, David Kirn
Science (New York, N.Y.)|December 9, 2021
Oncolytic virotherapy as immunotherapyAlan Melcher, Kevin Harrington, Richard Vile
The New England Journal of Medicine|September 9, 2008
Cancer immunotherapyRobin Prestwich, Richard Vile, Alan Melcher
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 2, 2009
Oncolytic viruses: time to compare, contrast, and combine? 5th international meeting on replicating oncolytic virus therapeutics. Banff, Alberta, Canada, 18-22 March 2009Hardev Pandha, Alan Melcher, Kevin Harrington, et al.
Oncotarget|September 12, 2012
The hitchhiker's guide to virotherapyOliver Donnelly, Richard Vile, Hardev Pandha, et al.
Pageof 10